For example, while CFRD remains a common comorbidity, partially driven by pancreatic damage and now potentially exacerbated by metabolic effects of newer therapies [6], emerging evidence suggests that CFTR modulators can have varied and interconnected effects, with some studies indicating potential for improved insulin secretion influencing glucose metabolism, while others suggest a possible unmasking of underlying glucose intolerance, further impacting nutritional status and overall metabolic health, necessitating careful monitoring [48]. Here, INS is linked to cystic fibrosis-related diabetes.